Prognostic factors in acute myeloid leukaemia

Best Practice and Research: Clinical Haematology

Volumn 14, Issue 1, 2001, Pages 65-75

  Löwenberg, Bob ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukaemia; Cytogenetics; Flt 3 mutations; Flt 3 receptor; Molecular genetics; Prognosis; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT; CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD34 ANTIGEN; CELL MARKER; DAUNORUBICIN; FLT3 LIGAND; GLYCOPROTEIN P; GROWTH FACTOR RECEPTOR; HEMOPOIETIC GROWTH FACTOR; HLA DR ANTIGEN; LUNG RESISTANCE PROTEIN; MICROSOMAL AMINOPEPTIDASE; MULTIDRUG RESISTANCE PROTEIN; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BLOOD ANALYSIS; CANCER CLASSIFICATION; CANCER SURVIVAL; CELL LINEAGE; CELL PROLIFERATION; CHILD; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 8; CLINICAL EXAMINATION; CONTROLLED STUDY; CYTOGENETICS; DRUG TRANSPORT; FEMALE; GENDER; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; INFANT; LEUKOCYTE COUNT; MALE; MOLECULAR GENETICS; MULTIDRUG RESISTANCE; MUTATION; MYELODYSPLASIA; NEUTROPENIA; PATIENT CARE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0035028824     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2000.0116     Document Type: Article

References (59)

1. Acute non-lymphocytic leukemia: Heterogeneity of stem cell origin
2. Further results in understanding the subpopulation structure in AML: Clonogenic cells and their progeny identified by differentiation markers
3. Clonogenic cells in acute myeloid leukemia
4. Rearrangements in the second intron of the RAR alpha gene are present in a large majority of patients with acute promyelocytic leukemia and are used as molecular markers for retinoic acid induced leukemia cell differentiation
5. A phase III trial comparing idarubicin and danorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group study
6. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia
7. Intensive postremission chemotherapy in adults with acute myeloid leukemia
8. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia
9. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A South West Oncology Group, Study
10. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: Results of MRC AML 10 trial
11. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission
12. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy
13. Treatment of the elderly patient with acute myeloid leukemia
14. Acute myeloid leukemia in the elderly in assessment of multidrug resistance (MDRI) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A South West Oncology Group Study
15. High-resolution chromosomes as an independent prognostic indicator in adult acute nonlymphocytic leukemia
16. Cytogenetic pattern in acute myelogenous leukemia: A major reproducible determinant of outcome
17. Clinical significance of cytogenetics in acute myeloid leukemia
18. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
19. MLL-rearrangements in haematological malignancies: Lessons from clinical and biological studies
20. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukemia derived from the MRC AML 10 trial
21. Immunophenotyping of AML and MDS and detection of residual disease
22. Prognostic implication of FLT 3 and N-RAS gene mutations in acute myeloid leukemia
23. Minimally differentiated acute nonlymphocytic leukemia: A distinct entity
24. Proposals for the recognition of minimally differentiated acute myeloid leukaemia
25. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukaemia (AML-MO)
26. AML-MO: Clinical entity or waste basket for immature blastic leukaemias? A description of 14 patients
27. Cytogenetic profile of minimally differentiated (FAB-MO) acute myeloid leukemia: Correlation with clinicobiologic findings
28. Myeloid/natural killer cell acute leukaemia: A previously unrecognized form of acute leukaemia potentially misdiagnosed as FAB-M3 acute myeloid leukaemia
29. Expression of constitutively activated human c-kit in myb transformed early myeloid cells leads to factor independence, histiocytic differentiation, and tumorigenicity
30. Frequency and clinical significance of the expression of the multidrug resistance proteins MDRI/P-glycoprotein, MRPI and LRP in acute myeloid leukemia. A South West Oncology Group Study
31. Expression of the multidrug resistance gene in myeloid leukemias
32. Multidrug resistance (MDRI) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity
33. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis
34. + leukemia cells
35. Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: Results of molecular and functional assays, and correlation with treatment outcome
36. Do P-glycoprotein and major vault (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?
37. Quality control of multidrug resistance assays in adult P-glycoprotein expression and activity
38. Simultaneous activity of MRPI and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia
39. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukemia cells predict a poor response to chemotherapy and reduce patient survival
40. P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy
41. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia
42. Overexpression of the major vault transporter protein lung-resistance protein predicts outcome in acute myeloid leukemia
43. P-glycoprotein, lung-resistance-related protein and multi-drug resistance associated protein in de novo acute non lymphocytic leukaemias: Biological and clinical implications
44. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia
45. Internal tandem duplication of the Flt-3 gene found in acute myeloid leukemia
46. Internal tandem publication of the Flt-3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: A study on a large series of patients and cell lines
47. Tandem duplications of the Flt-3 receptor gene are associated with leukemic transformation of myelodysplasia
48. Internal tandem duplication of Flt-3 associated with leukocytosis in acute promyelocytic leukemia
49. Human acute myeloid leukemia cells with internal tandem duplications in the Flt-3 gene show reduced proliferative ability in stroma supported long-term cultures
50. C-Kit protooncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukemia
51. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene
52. Expression of the c-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance
53. The expression of the proto oncogene c-kit in the blast cells of acute myeloblastic leukemia
54. C-fms expression is a marker of human acute myeloid leukemias
55. C-kit mutations in core binding leukemias
56. Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidizone and cytosine, arabinoside, vincristine and prednisone (ROAP)
57. Acute myeloid leukemia
58. Bi-allelic and heterozygous point mutation in the runt domain of the AMLI/PEBP2αB gene associated with acute myeloblastic leukemia
59. Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years; a retrospective analysis of the European Bone Marrow Transplant Group